Recent Updates
Recently added Catalysts
XAIR Positive Sentiment

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

Key Takeaway: Beyond Air, Inc. announced its participation in the D. Boral Capital Global Conference 2026, scheduled for May 7th at The Plaza Hotel in New York. CEO Robert Goodman and CFO Dan Moorhead will represent the company. Beyond Air focuses on using nitric oxide to treat respiratory illnesses and has received FDA approval for its LungFit PH system.
Price reaction · baseline $0.57 (2026-04-14 close) · hit after-hours · clean, no other XAIR news in the window
day 0 close
-11.6%
day 1 · peak
-21.9%
day 3
-4.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a significant global conference
  • Opportunity for one-on-one meetings with investors
  • Focus on improving patients' lives with innovative technology
  • FDA approval for their medical device, LungFit PH

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
Nitric Oxide
Phase 3 · Bronchiolitis

Full Press Release Details

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.
Conference
Format: One-on-one meetings
Conference Dates: May 7th
Participants: Robert Goodman, CEO, and Dan Moorhead, CFO of Beyond Air
If you are interested in requesting a one-on-one meeting at the conference, please contact your D. Boral Capital representative to schedule accordingly.

About Beyond Air, Inc.

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visitwww.beyondair.net.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to the commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s long-term strategic and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management.
Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully execute its commercial strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively, obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.

Frequently Asked Questions

What is the D. Boral Capital Global Conference 2026?

It is a significant event where companies like Beyond Air present their innovations.

Who will represent Beyond Air at the conference?

CEO Robert Goodman and CFO Dan Moorhead will represent Beyond Air.

What is the focus of Beyond Air's technology?

Beyond Air focuses on using nitric oxide to treat respiratory illnesses.

What approval has Beyond Air received for its product?

Beyond Air has received FDA approval for its LungFit PH system.

Last updated: Apr 15, 2026